Voyager Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Voyager Therapeutics zullen naar verwachting dalen met respectievelijk 11.7% en 28.8% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 19.9% per jaar.

Belangrijke informatie

-28.8%

Groei van de winst

-19.9%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	-11.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:VT6 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	69	-107	-60	-55	7
12/31/2025	60	-111	-105	-103	10
12/31/2024	89	-55	-29	-25	9
9/30/2024	164	26	-29	-25	N/A
6/30/2024	144	9	-22	-18	N/A
3/31/2024	119	-3	8	13	N/A
12/31/2023	250	132	75	78	N/A
9/30/2023	158	52	86	89	N/A
6/30/2023	195	96	91	94	N/A
3/31/2023	191	99	74	77	N/A
12/31/2022	41	-46	-15	-13	N/A
9/30/2022	71	-17	9	11	N/A
6/30/2022	31	-60	4	6	N/A
3/31/2022	32	-71	1	2	N/A
12/31/2021	37	-71	-55	-54	N/A
9/30/2021	16	-93	-92	-87	N/A
6/30/2021	132	18	-100	-91	N/A
3/31/2021	160	39	-100	-89	N/A
12/31/2020	171	37	-109	-97	N/A
9/30/2020	197	40	-110	-98	N/A
6/30/2020	100	-61	-103	-95	N/A
3/31/2020	117	-41	-113	-105	N/A
12/31/2019	104	-44	41	49	N/A
9/30/2019	74	-54	43	48	N/A
6/30/2019	55	-59	47	52	N/A
3/31/2019	12	-96	57	61	N/A
12/31/2018	8	-88	-20	-16	N/A
9/30/2018	12	-78	-10	-6	N/A
6/30/2018	11	-81	N/A	-5	N/A
3/31/2018	10	-74	N/A	2	N/A
12/31/2017	10	-71	N/A	-61	N/A
9/30/2017	6	-74	N/A	-60	N/A
6/30/2017	8	-59	N/A	-54	N/A
3/31/2017	11	-50	N/A	-47	N/A
12/31/2016	14	-40	N/A	-42	N/A
9/30/2016	17	-34	N/A	-39	N/A
6/30/2016	18	-32	N/A	-36	N/A
3/31/2016	20	-30	N/A	-33	N/A
12/31/2015	17	-38	N/A	41	N/A
9/30/2015	12	-35	N/A	46	N/A
6/30/2015	7	-32	N/A	50	N/A
3/31/2015	3	-30	N/A	55	N/A
12/31/2014	N/A	-18	N/A	-12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van VT6 zal naar verwachting de komende 3 jaar dalen ( -28.8% per jaar).

Winst versus markt: De winst van VT6 zal naar verwachting de komende 3 jaar dalen ( -28.8% per jaar).

Hoge groeiwinsten: De winst van VT6 zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van VT6 zal naar verwachting de komende 3 jaar dalen ( -11.7% per jaar).

Hoge groei-inkomsten: De omzet van VT6 zal naar verwachting de komende 3 jaar dalen ( -11.7% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VT6 naar verwachting over 3 jaar hoog zal zijn

Voyager Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023)

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 23%

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023)

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023)

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

President recently sold €90k worth of stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New major risk - Shareholder dilution

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Investor sentiment improves as stock rises 26%

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022)

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold €91k worth of stock

Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022)

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment deteriorates as stock falls 16%

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 19%

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022)

President recently sold €54k worth of stock

Chief Operating Officer recently sold €120k worth of stock

Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021)

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021)

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021)

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. Announces Executive Appointments

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020)

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019)

Revenue misses expectations